Table 1.

Clinicopathologic features, tumor markers, and patient survival

Variable	Total n	5-y DFS (%)	HR (95% CI)	P*	5-y OS (%)	HR (95% CI)	P*
Age (10-y increase)	431	NA	1.09 (0.94–1.27)	0.2445	NA	1.21 (1.03–1.41)	0.0177
Gender
Female	203 (47%)	63.5%	–	0.5758	70.4%	–	0.7029
Male	228 (53%)	61.1%	1.09 (0.80–1.49)		70.6%	1.06 (0.78–1.44)
TNM stage
II	85 (20%)	78.8%	–	0.0013	84.7%	–	0.0012
III	346 (80%)	58.2%	2.19 (1.34–3.59)		67.0%	2.16 (1.34–3.49)
T stage†
T1-T2	48 (13%)	62.4%	–	0.8091	75.0%	–	0.3710
T3-T4	334 (87%)	64.5%	0.94 (0.57–1.55)		72.4%	0.81 (0.51–1.29)
Grade‡
1, 2	291 (68%)	64.1%	–	0.1260	73.9%	–	0.0411
3, 4	140 (32%)	58.4%	1.29 (0.93–1.77)		63.6%	1.39 (1.01–1.90)
Treatment§
Ineffective/control	49 (11%)	46.9%	–	0.0168	53.1%	–	0.0163
Effective	382 (89%)	64.2%	0.60 (0.40–0.92)		72.8%	0.60 (0.40–0.92)
Tumor site
Distal	215 (50%)	61.2%	–	0.5427	70.7%	–	0.8470
Proximal	216 (50%)	63.3%	0.91 (0.67–1.24)		70.4%	0.97 (0.72–1.32)
Bim
Negative	66 (18%)	53.0%	–	0.0225	66.7%	–	0.0334
Elevated	295 (82%)	64.5%	0.62 (0.42–0.94)		71.5%	0.65 (0.44–0.97)
Puma
Negative/low§	37 (9%)	51.4%	–	0.1261	64.9%	–	0.0220
Elevated	379 (91%)	63.4%	0.68 (0.42–1.12)		71.0%	0.59 (0.37–0.93)
Noxa
Negative/low§	146 (35%)	67.8%	–	0.1606	74.7%	–	0.5442
Elevated	271 (65%)	60.3%	1.28 (0.91–1.80)		69.0%	1.11 (0.80–1.54)
Bim + Puma§
Immunoscore sum ≤4	63 (18%)	47.6%	–	0.0007	60.3%	–	0.0002
Immunoscore sum >4	289 (82%)	65.9%	0.51 (0.34–0.76)		73.0%	0.48 (0.33–0.71)
MMR
Intact MMR	334 (90%)	62.1%	–	0.1533	70.3%	–	0.2155
Defective MMR	36 (10%)	72.2%	0.63 (0.33–1.20)		80.6%	0.68 (0.36–1.26)
p53†
Negative	50 (36%)	62.0%	–	0.3150	74.0%	–	0.4522
Positive	88 (64%)	49.9%	1.32 (0.77–2.28)		59.1%	1.22 (0.72–2.08)

Abbreviation: NA, not available.

^*Score test P value from a Cox regression model after stratifying by study.

^†Missing cases.

^‡Grade 1 and 2 (well/moderate); grade 3 and 4 (poor/undifferentiated).

^§See Materials and Methods.